Efficacy and tolerability of losartan in hypertensive patients with renal impairment

Hypertension

Volumn 31, Issue 2, 1998, Pages 684-691

  Toto, Robert ^a,c   Shultz, Pamela ^a   Raij, Leopoldo ^a   Mitchell, Helen ^a   Shaw, Wayne ^a   Ramjit, Denise ^b   Toll, Jenny ^b   Shahinfar, Shahnaz ^b  

^a University of Texas Southwestern at Dallas   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Hemodialysis; Losartan; Renal insufficiency; Renin angiotensin aldosterone system

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; LOSARTAN;

ADULT; AGED; ARTICLE; ASTHENIA; BREATHING DISORDER; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; GRAFT OCCLUSION; HEADACHE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREMOR; VERTIGO; VOMITING; WEIGHT GAIN;

EID: 0031951792     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.31.2.684     Document Type: Article

References (28)

1. Campese VM, Bigazzi R. Clinical factors in progressive renal injury. Am J Kidney Dis. 1991;17(suppl l):43-47.
2. Hannedouche T, Chauveau P, Kalou F, Albouze G, Lacour B, Jungers P. Factors affecting progression in advanced chronic renal failure. Clin Nephrol. 1993;39:312-320.
3. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989;35:670-674.
4. Walker GW. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis. 1993;22:164-173.
5. United States Renal Data Systems. Annual Data Report. Chapters 5-6: Incidence and causes of treated ESRD-patient survival; 1994:43-94.
6. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286-290.
7. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990:25:458-482.
8. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effort of initial anti-hypertensive treatment. Scand J Clin Lab Invest. 1976;36:383-388.
9. Lewis EJ, Hunsicker L, Bain RP, Rhode RD. The effect of angiotensinconverting enzyme on diabetic nephropathy. N Engl J Med. 1993;329: 1456-1462.
10. Toto RD, Mitchell H, Mclntire D, Smith R, Pettinger WA. Strict blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995:48:851-859.
11. Kamper AL, Straandgarrd S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure: A randomized controlled trial. Am J Hypertens. 1992;5:423-430.
12. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N EnglJ Med. 1994; 330:877-884.
13. Johnston CI. Angiotensin II receptor antagonists: focus on losartan. Lancet. 1995;346:1403-1407.
14. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely, DB, Sweet, CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25: 1345-1350.
15. Ruilope LM, Simpson RL, Toh J, Arcuri KE, Goldberg AI, Sweet CS. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Pressure. 1996;5:32-40.
16. Dahlof B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am] Hypertension. 1995;8:578-583.
17. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB. Nonpeptide angiotensin II receptor antagonists, XI: pharmacology of EXP3174, an active metabolite of DuP753, an orally active antihypertensive agent. J Pharrrucol Exp Ther. 1990;255: 211-217.
18. Sica DA, Lo MW, Shaw WC, Keane WF, Gehr TWB, Halstenson CE, Lipschutz K, Furtek CI, Ritter MA, Shahinfâr S. The pharmacokinetics of losartan in renal insufficiency. J Hypcrtcns. 1995;13:S49-S52.
19. Waiser M, Davidson DG, Orloff J. The renal clearance of alkali-stable inulin-jain Invest. 1995:34:1520-1523.
20. Converse RL, Jacobsen TG, Jost CM, Consenrino F, Tarazi F, Victor R. Sympathetic overactivity in patients with chronic renal failure. N Engl }Med. 1992:327:1912-1918.
21. Liou HH, Huang TP, Campese VM. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes with non-diabetic renal diseases. AVp/in?H. 1995:69:41-48.
22. Djorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304:339-343.
23. Hannedouche T, Landais P, Goldfard B, El Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suc JM, GrunfeldJP. Randomized controlled trial of enalapril and -blockers in non-diabetic chronic renal failure. BMJ. 1994:309:833-837.
24. Gansevoort RT, de Zeeuw D, Shahinfar S, Redficld A, de Jong P. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal impairment. J Hypertens. 1994;12(suppl 2):S37-S42.
25. Gansevoort RT, de Zeeuw D, de Jong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861-867.
26. Tannen RL. Disorders of potassium balance. In: Brenner DM, Rector FC, eds. The Kidney. 4th ed. Philadelphia, Pa: WB Saunders Co; 1991; 805-840.
27. Mallion JM, Bradstreet DC, Makris L, Goldberg AI, Halasz S, Sweet CS, Lim NY, Madonna O. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients \vith mild to moderate essential hypertension. J Hyperlens. 1995;13(suppl 1):S35-S41.
28. Eschbach JW, Adamson JW. Hématologie consequences of renal failure. In: Brenner BM, Rector FC, eds. Ttie Kidney. 4th ed. Philadelphia, Pa: WB Saunders Co; 1991:2019-2035.